Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.6 (
RNA polymerase
)
34,946
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Long noncoding RNAs (lncRNAs) are vital players in cancers, including hepatocellular carcinoma (HCC). We previously identified an lncRNA,
GAS8
-AS1
, that is located in intron 2 of
GAS8
However, its involvement in HCC is still largely unknown. In this study, we report that both
GAS8
-AS1
and its host gene
GAS8
act as HCC tumor suppressors. We found that expression of
GAS8
-AS1
or
GAS8
is significantly decreased in HCC tissues and is associated with a poor prognosis among HCC patients. Interestingly, lncRNA
GAS8
-AS1 could promote
GAS8
transcription. We detected a CpG island in the
GAS8
promoter, but lncRNA
GAS8
-AS1 did not affect DNA methylation at this
GAS8
promoter site. Moreover, we identified two
GAS8
-AS1-interacting proteins, mixed-lineage leukemia 1 (MLL1), a histone 3 Lys-4 (H3K4) methyltransferase, and its partner WD-40 repeat protein 5 (WDR5). RNA pulldown, ChIP, and RNA immunoprecipitation assays revealed that
GAS8
-AS1 is required for maintaining the
GAS8
promoter in an open chromatin state by recruiting the MLL1/WDR5 complex and for enhancing
RNA polymerase II
activity and
GAS8
transcription. Of note,
GAS8
-AS1-dependent
GAS8
hyperactivation inhibited malignant transformation of hepatocytes. Our results provide important insights into how lncRNA
GAS8
-AS1 suppresses HCC development and suggest potential strategies for treating patients with liver cancer.
...
PMID:The long noncoding RNA
GAS8-AS1
suppresses hepatocarcinogenesis by epigenetically activating the tumor suppressor
GAS8
. 3022 80